46
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      On the future of therapeutic vaccination in chronic hepatitis B

      editorial
      * , 1
      Future Science OA
      Future Science Ltd
      chronic hepatitis B, clinical trials, vaccination

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          According to the WHO, approximately 254 million patients are chronic carriers of hepatitis B virus (HBV) and the fatalities are in the range of 0.5 to 1 million patients per year [1]. Only a small fraction of patients requiring treatment are on therapy. Untreated patients are at risk of suffering liver cirrhosis and hepatocellular carcinoma. Chronic hepatitis B (CHB) is one of the diseases where therapeutic vaccination has been tested with enthusiasm and hope, due to the limitations and low effectiveness [2] of current treatments. Although hepatitis B commercial vaccines are efficient in preventing HBV infection, they have failed in the therapeutic setting, leading to the development of more potent vaccine candidates. Therapeutic vaccination can be conceptualized as the immunization strategy aimed at activating or modifying the immune system in order to cure, control or limit the progression of a specific pathological condition, using an active and specific stimulation of the immune system. This therapeutic approach has been attempted in the fields of chronic infectious diseases, cancer, autoimmunity, allergy and the treatment of addiction to several drugs. The working hypothesis of therapeutic vaccination in the field of CHB is based on the understanding of the immunological profile of patients with natural- or treatment-induced serological and virological responses, in contrast to the profile induced in those unable to control HBV replication and the related liver damage. Mimicking this immune profile, several vaccine candidates were developed and tested. Even after the exciting Phase I/II results, several companies have stopped studies with their candidates since they failed to fulfill specific clinical end points in subsequent trials. A closer look into these clinical results is required. Actions have been taken to improve therapeutic vaccines: inclusion of new antigens; the use of different routes of administration; changes in the vaccination schedule; the inclusion of potent adjuvants; the optimization of the antigen dose, etc. One of the reasons of their failure may be the fact that most of these clinical trials were conducted in patients under a deep and long-standing viral suppression [3–5]. The rationale of therapeutic vaccination when administered under viral suppression, is based on the observation that a decrease in viral load often precedes the detection of anti-HBV-specific T-cell responses, both in patients resolving natural infections and in those achieving HBeAg seroconversion during the chronic infection. Thus, a reduction in HBV load by antiviral treatment with nucleot(s)ide analogs (NUC) may increase the responsiveness of HBV-specific T cells, which are hyporesponsive in cases of persistent HBV infection [6]. However, changes in viral load have immunological repercussion. Increased HBV-specific T-cell responses are detectable during the first few months of lamivudine treatment [7]; however, this restoration of T-cell activity is partial, transient and does not lead to an increase in HBeAg seroconversion [8], suggesting that the timing for vaccination is a relevant variable. On the other hand, the patients restarted NUC treatment very soon after discontinuation, just after the first detection of HBV DNA, or when there was evidence of HBV replication at low levels [9–11], following a conservative approach. There are some theoretical disadvantages related to immunizing patients under long-term antiviral treatment. Vaccine-induced T cells should exert their function in the liver. However, the anti-inflammatory liver environment is reinforced, as reflected by the reduction in alanine amino transferase (ALT) levels in most patients few weeks after the start of antiviral treatment [9–11]. In line with this, it has been demonstrated that hepatocytes do not express HLA class II, except under inflammatory conditions [12–14], a logical and natural adaptation to the tolerogenic role of the liver, further reducing the antigenicity of hepatocytes in patients without treatment. The suppression of viral replication in patients under NUC therapy leads to a reduction in the number of hepatocytes presenting viral antigens, such as cytoplasmic HBcAg. It has been demonstrated that the control of the replication can be predicted by the low intracellular expression of HBcAg [15]. Taken together, in virally suppressed patients, there is a reduced presentation of HBV antigens and consequently a reduction in the presentation of viral peptides to vaccine-induced T cells both by HLA class I and II. Viral replication reactivates the immune system detection mechanisms, restarting the immune response. In fact, nucleo(s/t)ide analog (NUC) treatment discontinuation may be useful for immunotherapeutic efficacy improvement; however the design of the discontinuation and restart treatment protocol needs to be changed. HeberNasvac, a therapeutic vaccine used as a monotherapy, was compared with pegylated interferon (PegIFN) in an efficacy Phase III clinical trial [16]. This product was shown to be safer than PegIFN and more effective in terms of HBV DNA suppression. HeberNasvac also demonstrated a better serological response and a slower progression of fibrosis, linked to a lower number of complications in the 5-year follow-up period when compared with PegIFN [17–21]. It is noteworthy that the recent, long-lasting studies comparing PegIFN with antivirals support the superiority of PegIFN for the prevention of unfavorable events (cirrhosis, hepatocellular carcinoma, death) [22], even when the suppression of HBV is less pronounced compared with the effect of antiviral treatment. In this context, HeberNasvac's superiority compared with PegIFN deserves a closer look by WHO and other international organizations due to the safety profile of this product, having the potential of being applied to all chronic hepatitis B patients. The sanitary registration granted to HeberNasvac in its country of origin (Cuba) as well as the first international activities with this product in Japan [23] and other countries in Asia, are encouraging news. HeberNasvac represents a finite and safe alternative for CHB treatment as a monotherapy. In addition, smart combinations with NUCs or PegIFN are also possible since it is a fully developed industrial product and, at present, administered in several hundreds of patients around the world as well as starting sanitary registration in several countries [24]. Future opportunities in the field of therapeutic vaccination There is still a long road ahead in the optimization of this product. In fact, the first clinical evaluation of HeberNasvac combined with NUC failed to demonstrate the expected efficacy according to the trial design [25,26]. Therapeutic vaccination combined with some of the novel therapeutic drugs under development [26] represents a wide opportunity for future research. However, the study of smart combinations with NUC treatment may overcome the immunological limitations found in past studies. Major associations for the study of the liver support antiviral treatment discontinuation under strict monitoring in noncirrhotic HBeAg-negative patients, with long-time virological suppression and low fibrosis. The recommendations of treatment discontinuation in HBeAg-negative patients was preceded by a strong meta-analysis that detected the increase of the anti-HBV immune response after NUC cessation, as a consequence of viral rebound. ALT increases, in patients with low levels of fibrosis and under strict assessment, are considered benign in nature and reflect an immune activation that leads to HBsAg elimination in 20–40% of the patients in the 3-year follow-up period. On the other hand, patients continuing treatment with NUCs evidenced no reduction in their serum HBsAg levels [27–30]. The European Association for the Study of the Liver (EASL) has established rules for restarting therapy based on the absence of response, or on a clear and sustained re-emergence of the ALT and HBV DNA. Transient and moderate ALT increases after viral rebound are considered physiologically normal. This is later naturally controlled by the immune system. After a solid meta-analysis [27], EASL guidelines proposed the restart of NUC treatment, several months after discontinuation and specific rules were put in place. The currently used clinical trial methodology should be adjusted to implement the novel guidelines proposed in patients discontinuing antiviral treatment. Such modifications favor the incorporation of patients currently under NUC treatment and wishing to stop antiviral treatment after several years. A potential increase in serological responses is likely to occur in such conditions [27]. Hence, a new horizon of opportunities is created for therapeutic vaccination approaches. A rational design of vaccination in the setting of NUC interruption may also contribute to find a solution for patients needing antiviral treatment cessation due to economic or medical reasons. In this group, ALT exacerbation post-treatment cessation is frequent. In fact, irregular medication with NUCs is one of the major causes of decompensation and acute on chronic liver failure [31]. Thus, the modulation in the pattern of immune response with the use of vaccination around or after treatment cessation, should modulate the immunological pattern associated with viral rebound and ALT exacerbation associated to decompensation, in favour of shorter and beneficial flares related to the Th1 immune response induced by the vaccine [32]. An approach already under study proposes the use of NUC for a longer period of time after therapeutic vaccination. This approach is intended to favor HBsAg seroconversion without losing the virological, serological and biochemical gain from NUC therapy. In the specific case of HBeAg-negative patients under NUC, HBsAg remains as the only serological variable. The accomplishment of this concept represents a new strategy; in short, more time is given to the immune system to work under virological suppression [23]. The results of this new trial should provide light on this novel approach, leading to NUC treatment discontinuation only after the consolidation of HBsAg elimination. In summary, therapeutic vaccination has the potential to modify immune reactivation after treatment cessation. Alternatively, the use of NUC for a longer period of time after therapeutic vaccination should favor HBsAg seroconversion without losing the virological, serological and biochemical gain from NUC therapy. Then, the future of therapeutic vaccination in CHB remains alive and strong, both as a monotherapy and in the setting of rationally combined treatments.

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine.

          Induction of curative immune responses by therapeutic vaccination in chronic viral infections such as chronic hepatitis B (CHB) is expected to be facilitated by reduction of viral load by antiviral treatment. In this open label, controlled, randomized study, 195 patients with HBeAg positive CHB were randomized to receive 12 doses of HBsAg with AS02B adjuvant candidate vaccine plus lamivudine daily for 52 weeks or lamivudine daily alone. The combined administration of vaccine and lamivudine was safe and well tolerated, but did not improve the HBe seroconversion rate (18.8%) when compared to treatment with lamivudine alone (16.1%) (p=0.6824). Despite induction of a vigorous HBsAg-specific lymphoproliferative response, cytokine production and anti-HBs antibodies, therapeutic vaccination with an adjuvanted HBsAg vaccine administered concomitantly with lamivudine did not demonstrate superior clinical efficacy in HBeAg positive CHB patients as compared to lamivudine therapy alone.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

            Lamivudine therapy in patients with chronic hepatitis B can induce the recovery of antiviral T cell responses. It is unknown whether the recovery of T cell responsiveness is long-lasting and persists throughout the treatment and whether the elevation of viremia which follows therapy withdrawal can restore a condition of T cell unresponsiveness. Frequency and function of circulating hepatitis B virus (HBV)-specific CD4 and CD8 cells from 12 hepatitis e surface antigen + patients with chronic hepatitis B were studied longitudinally before, during and after lamivudine therapy by intracellular cytokine staining, proliferation and cytotoxicity assays against HBV proteins and peptides. CD4-mediated responses were analyzed in all patients, whereas CD8 cells were studied in 6 HLA-A2+ patients. HBV-specific CD4 and CD8 reactivity showed a bi-phasic behavior under lamivudine therapy with an early enhancement of T cell frequency and intensity of responses followed by a persistent decline starting from the 5th to 6th month of treatment. Since restoration of HBV-specific T cell reactivity is only transient, our study indicates that therapeutic stimulation of HBV-specific T cell responses to complement lamivudine treatment should be done early after the initiation of lamivudine. Moreover, the transient nature of the immune reconstitution may represent a favorable condition for virus reactivation once lamivudine therapy is withdrawn.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B.

              This prospective study investigated viral and host markers after stopping long-term therapy with nucleos(t)ide analogues in noncirrhotic patients with hepatitis B e antigen-negative chronic hepatitis B. After stopping therapy, 13 of 15 patients experienced a virological relapse. Rebound of hepatitis B virus DNA and hepatitis B core-related antigen was associated with induction of plasma tumor necrosis factor, interleukin (IL) 10 , IL-12p70, CXCL10 and subsequent decline in hepatitis B surface antigen (HBsAg), with 20% HBsAg loss after long-term follow-up. The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after cessation of therapy were positively correlated with the level of HBsAg decline at week 48. Thus, stopping or interrupting NA treatment should be further investigated as a strategy to accelerate HBsAg loss.
                Bookmark

                Author and article information

                Journal
                Future Sci OA
                Future Sci OA
                FSOA
                Future Science OA
                Future Science Ltd (London, UK )
                2056-5623
                30 October 2019
                December 2019
                30 October 2019
                : 5
                : 10
                : FSO426
                Affiliations
                [1 ]Head, Hepatitis B Therapeutic Vaccine Project, Center for Genetic Engineering & Biotechnology Ave. 31/158 & 190, Playa, Havana 10600, Cuba
                Author notes
                [* ]Author for correspondence: Tel.: +53 5357 4176; julio.aguilar@ 123456cigb.edu.cu
                Article
                10.2144/fsoa-2019-0104
                6900968
                31827895
                356fc669-3bd8-4197-a6e5-bb2e5e2c65ae
                © 2019 Julio Cesar Aguilar Rubido

                This work is licensed under the Creative Commons Attribution 4.0 License

                History
                : 05 September 2019
                : 19 September 2019
                : 30 October 2019
                Page count
                Pages: 4
                Categories
                Editorial

                chronic hepatitis b,clinical trials,vaccination
                chronic hepatitis b, clinical trials, vaccination

                Comments

                Comment on this article